Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Trainer

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Bailliere'S Best Practice & Research. Clinical Endocrinology & Metabolism|July 26, 2000
Growth hormone receptor antagonists therapy for acromegalyC Parkinson, P J Trainer
Expert Opinion on Investigational Drugs|January 5, 2002
The place of pegvisomant in the management of acromegalyC Parkinson, P J Trainer
Clinical Endocrinology|April 1, 1991
The diagnosis and differential diagnosis of Cushing's syndromeP J Trainer, A Grossman
Clinical Endocrinology|November 26, 1998
Endocrine investigation: Cushing's syndromeR J Ross, P J Trainer
The European Journal of Medicine|May 1, 1993
Differential diagnosis in Cushing's syndrome: the role of inferior petrosal sinus samplingP J Trainer, G M Besser
Experimental Physiology|July 12, 2008
Growth hormone excess and the development of growth hormone receptor antagonistsC E Higham, P J Trainer
Clinical Endocrinology|September 1, 1995
The effect of an opiate antagonist on the hormonal changes induced by hexarelinM Korbonits, P J Trainer, G M Besser
The Journal of Clinical Endocrinology and Metabolism|November 10, 2001
The relationship between serum GH and serum IGF-I in acromegaly is gender-specificC Parkinson, W D Ryder, P J Trainer, et al.
Advanced Drug Delivery Reviews|September 23, 2003
Pegvisomant in the treatment of acromegalyC Parkinson, J A Scarlett, P J Trainer
Clinical Endocrinology|March 29, 2007
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problemsA N Paisley, M E Roberts, P J Trainer
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Bailliere'S Best Practice & Research. Clinical Endocrinology & Metabolism|July 26, 2000
Growth hormone receptor antagonists therapy for acromegalyC Parkinson, P J Trainer
Expert Opinion on Investigational Drugs|January 5, 2002
The place of pegvisomant in the management of acromegalyC Parkinson, P J Trainer
Clinical Endocrinology|April 1, 1991
The diagnosis and differential diagnosis of Cushing's syndromeP J Trainer, A Grossman
Clinical Endocrinology|November 26, 1998
Endocrine investigation: Cushing's syndromeR J Ross, P J Trainer
The European Journal of Medicine|May 1, 1993
Differential diagnosis in Cushing's syndrome: the role of inferior petrosal sinus samplingP J Trainer, G M Besser
Experimental Physiology|July 12, 2008
Growth hormone excess and the development of growth hormone receptor antagonistsC E Higham, P J Trainer
Clinical Endocrinology|September 1, 1995
The effect of an opiate antagonist on the hormonal changes induced by hexarelinM Korbonits, P J Trainer, G M Besser
The Journal of Clinical Endocrinology and Metabolism|November 10, 2001
The relationship between serum GH and serum IGF-I in acromegaly is gender-specificC Parkinson, W D Ryder, P J Trainer, et al.
Advanced Drug Delivery Reviews|September 23, 2003
Pegvisomant in the treatment of acromegalyC Parkinson, J A Scarlett, P J Trainer
Clinical Endocrinology|March 29, 2007
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problemsA N Paisley, M E Roberts, P J Trainer
Pageof 11